Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers.

GPT-5.6 Sol Pro disproved a 20-year-old statistics conjecture in 90 minutes that GPT-5.5 couldn't crack in over 20 hours — a ...

Thermodynamic computing crossed a credibility threshold this week as peer-reviewed papers from Lawrence Berkeley National ...

Illumina, Inc. today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer Formation Bio. As leaders in AI-driven drug discovery, ...

Leaked Documents Reveal Specialised Cover for India’s Nuclear Facility Amid Concerns Over Reliance Group Servers and Dark Web Leak ...

AI agent dispute resolution reached a milestone July 10 when GenLayer Foundation led 27 firms in launching Internet Court, a ...

Economic asymmetry after cartridge introduction drives a design philosophy centered on minimizing false acceptances and protecting API, with >99.5% first-pass yield as the principal success criterion.

Palantir must achieve ~$42B in revenue and a 61% FCF margin by 2030 to justify its current valuation. See why I rate PLTR ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

Understanding online pokies mechanics makes every session more informed. Here's how RNG, reels, paylines, and features work for Australian players.

Salt substitution was deemed cost-saving—producing better health outcomes at lower costs. Comprehensive adoption of potassium ...